Evozyne
United States
- Chicago, IL
- 28/09/2023
- Series B
- $81,000,000
Evozyne combines evolution and deep learning technology to create highly functional novel proteins — Natural Machines™ — to solve longstanding challenges in therapeutics and sustainability. By amplifying a protein’s function based on the rules of nature, we address complex, high-impact problems. From developing life-changing patient treatments to making carbon capture a reality, Evozyne is committed to making a healthier, more sustainable world.
- Industry Biotechnology
- Website https://www.evozyne.com/
- LinkedIn https://www.linkedin.com/company/evozyne/about/
Related People
Mike GamsonFounder
United States -
Greater Chicago Area
I'm passionate about leading teams to pursue inspiring goals. I love working with intellectually curious people who can do anything, but show up everyday with humility and a drive to be better than they were yesterday. I believe that driving results matters as does taking the time in life to stop to smell the roses. I aspire to be a great colleague and I hope to be a student of new things forever.
SavvyMoney | $225,000,000 | (Oct 28, 2025)
WorkHero | $5,000,000 | (Oct 28, 2025)
Honey Health | $7,800,000 | (Oct 28, 2025)
Paygentic | $2,000,000 | (Oct 28, 2025)
Natural | $9,800,000 | (Oct 28, 2025)
PodPlay Technologies | $8,000,000 | (Oct 28, 2025)
Seneca | $60,000,000 | (Oct 28, 2025)
Serval | $47,000,000 | (Oct 28, 2025)
Bridge(US) | $5,100,000 | (Oct 28, 2025)
Vermeer | $10,000,000 | (Oct 24, 2025)
Apriority Financial, Inc. | $2,300,000 | (Oct 24, 2025)
GradBridge | $20,000,000 | (Oct 24, 2025)